Literature DB >> 20935021

A modified toxicity probability interval method for dose-finding trials.

Yuan Ji1, Ping Liu, Yisheng Li, B Nebiyou Bekele.   

Abstract

BACKGROUND: Building on earlier work, the toxicity probability interval (TPI) method, we present a modified TPI (mTPI) design that is calibration-free for phase I trials.
PURPOSE: Our goal is to improve the trial conduct and provide more effective designs while maintaining the simplicity of the original TPI design.
METHODS: Like the TPI method, the mTPI consists of a practical dose-finding scheme guided by the posterior inference for a simple Bayesian model. However, the new method proposes improved dose-finding decision rules based on a new statistic, the unit probability mass (UPM). For a given interval and a probability distribution, the UPM is defined as the ratio of the probability mass of the interval to the length of the interval.
RESULTS: The improvement through the use of the UPM for dose finding is threefold: (1) the mTPI method appears to be safer than the TPI method in that it puts fewer patients on toxic doses; (2) the mTPI method eliminates the need for calibrating two key parameters, which is required in the TPI method and is a known difficult issue; and (3) the mTPI method corresponds to the Bayes rule under a decision theoretic framework and possesses additional desirable large- and small-sample properties. LIMITATION: The proposed method is applicable to dose-finding trials with a binary toxicity endpoint.
CONCLUSION: The new method mTPI is essentially calibration free and exhibits improved performance over the TPI method. These features make the mTPI a desirable choice for the design of practical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20935021      PMCID: PMC5038924          DOI: 10.1177/1740774510382799

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  13 in total

1.  Practical implementation of a modified continual reassessment method for dose-finding trials.

Authors:  S Piantadosi; J D Fisher; S Grossman
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

2.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

3.  Some practical improvements in the continual reassessment method for phase I studies.

Authors:  S N Goodman; M L Zahurak; S Piantadosi
Journal:  Stat Med       Date:  1995-06-15       Impact factor: 2.373

4.  Sequential designs for phase I clinical trials with late-onset toxicities.

Authors:  Y K Cheung; R Chappell
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

5.  Cancer phase I clinical trials: efficient dose escalation with overdose control.

Authors:  J Babb; A Rogatko; S Zacks
Journal:  Stat Med       Date:  1998-05-30       Impact factor: 2.373

6.  Sensitivity of dose-finding studies to observation errors.

Authors:  Sarah Zohar; John O'Quigley
Journal:  Contemp Clin Trials       Date:  2009-07-04       Impact factor: 2.226

7.  The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.

Authors:  Z Yuan; R Chappell; H Bailey
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

8.  Model calibration in the continual reassessment method.

Authors:  Shing M Lee
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

Review 9.  Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.

Authors:  P F Thall; S-J Lee
Journal:  Int J Gynecol Cancer       Date:  2003 May-Jun       Impact factor: 3.437

10.  A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.

Authors:  Alexia Iasonos; Andrew S Wilton; Elyn R Riedel; Venkatraman E Seshan; David R Spriggs
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

View more
  55 in total

1.  Performance of toxicity probability interval based designs in contrast to the continual reassessment method.

Authors:  Bethany Jablonski Horton; Nolan A Wages; Mark R Conaway
Journal:  Stat Med       Date:  2016-07-19       Impact factor: 2.373

2.  Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Julie R Brahmer; Rosalyn A Juergens; Hossein Borghaei; Scott Gettinger; Laura Q Chow; David E Gerber; Scott A Laurie; Jonathan W Goldman; Frances A Shepherd; Allen C Chen; Yun Shen; Faith E Nathan; Christopher T Harbison; Scott Antonia
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

3.  Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.

Authors:  Yuan Ji; Sue-Jane Wang
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

4.  Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

Authors:  Ying Yuan; Kenneth R Hess; Susan G Hilsenbeck; Mark R Gilbert
Journal:  Clin Cancer Res       Date:  2016-07-12       Impact factor: 12.531

Review 5.  Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority.

Authors:  Ying Yuan; J Jack Lee; Susan G Hilsenbeck
Journal:  JCO Precis Oncol       Date:  2019-10-24

6.  Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Authors:  Philippe B Pierrillas; Sylvain Fouliard; Marylore Chenel; Andrew C Hooker; Lena E Friberg; Mats O Karlsson
Journal:  AAPS J       Date:  2018-03-07       Impact factor: 4.009

7.  Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

Authors:  Michael B Atkins; Elizabeth R Plimack; Igor Puzanov; Mayer N Fishman; David F McDermott; Daniel C Cho; Ulka Vaishampayan; Saby George; Thomas E Olencki; Jamal C Tarazi; Brad Rosbrook; Kathrine C Fernandez; Mariajose Lechuga; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2018-02-10       Impact factor: 41.316

8.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

9.  Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Authors:  Diwakar Davar; Hong Wang; Joe-Marc Chauvin; Ornella Pagliano; Julien J Fourcade; Mignane Ka; Carmine Menna; Amy Rose; Cindy Sander; Amir A Borhani; Arivarasan Karunamurthy; Ahmad A Tarhini; Hussein A Tawbi; Qing Zhao; Blanca H Moreno; Scott Ebbinghaus; Nageatte Ibrahim; John M Kirkwood; Hassane M Zarour
Journal:  J Clin Oncol       Date:  2018-10-25       Impact factor: 44.544

10.  Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.

Authors:  Ying Yuan; Ruitao Lin; Daniel Li; Lei Nie; Katherine E Warren
Journal:  Clin Cancer Res       Date:  2018-05-16       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.